ArticleDrug design, development and therapy2026
Effects of Edaravone Treatment on Endometriotic Lesion Sizes in a Surgically Induced Rat Model: A Pilot Study.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endometriosis is a chronic, oestrogen-dependent inflammatory disorder associated with elevated systemic oxidative stress. Current medical therapies are limited by significant side effects and high recurrence rates, underscoring the need for novel therapeutic strategies. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) is a clinically approved synthetic free radical scavenger with established antioxidant and anti-inflammatory properties, representing a candidate for drug repurposing in endometriosis. Methods: Ten female Wistar Albino rats underwent surgical endometriosis induction using the Vernon and Wilson method. After four weeks, lesion sizes were measured at a second laparotomy using a digital calliper (baseline). Animals were randomly allocated to an edaravone-treated group (n=6; 3 mg/kg/day subcutaneously for 28 days) or a saline control group (n=4). Lesion sizes were re-measured at a third laparotomy and tissue samples were collected for histological examination (haematoxylin and eosin staining). Between-group changes were compared using the Mann-Whitney Results: In the edaravone group, mean lesion size decreased from 2.40 ± 0.52 mm to 1.91 ± 0.54 mm (mean change: -0.50 mm; -17.0%). In the control group, mean lesion size increased from 4.47 ± 1.89 mm to 4.79 ± 2.02 mm (mean change: +0.32 mm; +7.09%). Baseline lesion size was larger in the control group than in the edaravone group, and this imbalance should be considered when interpreting the findings. The between-group difference in absolute lesion size change was statistically significant (Mann-Whitney Conclusion: In this pilot study, edaravone-treated animals showed reduced lesion size relative to controls; however, the within-group reduction was not statistically significant, baseline lesion size differed between groups, and no mechanistic markers were measured. These preliminary, hypothesis-generating findings should be interpreted with caution and warrant larger, adequately powered, mechanistically comprehensive studies before any therapeutic potential of edaravone in endometriosis can be inferred.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.